Skip to main content
Erschienen in: Drug Safety 10/2003

01.08.2003 | Leading Article

Drug Adverse Reaction Target Database (DART)

Proteins Related to Adverse Drug Reactions

verfasst von: Zhi Liang Ji, Lian Yi Han, Chun Wei Yap, Li Zhi Sun, Xin Chen, Dr Yu Zong Chen

Erschienen in: Drug Safety | Ausgabe 10/2003

Einloggen, um Zugang zu erhalten

Abstract

An adverse drug reaction (ADR) often results from interaction of a drug or its metabolites with specific protein targets important in normal cellular function. Knowledge about these targets is both important in facilitating the study of the mechanisms of ADRs and in new drug discovery. It is also useful in the development and testing of rational drug design and safety evaluation tools. The Drug Adverse Reaction Database (DART) is intended to provide comprehensive information about adverse effect targets of drugs described in the literature. Moreover, proteins involved in adverse effect targets of chemicals not yet confirmed as ADR targets are also included as potential targets. This database gives physiological function of each target, binding drugs/agonists/antagonists/activators/inhibitors, IC50 values of the inhibitors, corresponding adverse effects, and type of ADR induced by drug binding to a target. Cross-links to other databases are also introduced to facilitate the access of information about the sequence, 3-dimensional structure, function, and nomenclature of each target along with drug/ligand binding properties, and related literature. The database currently contains entries for 147 ADR targets and 89 potential targets. A total of 187 adverse reaction conditions, 257 drugs, and 1080 ligands known to bind to each of these targets are also currently described. Each entry can be retrieved through multiple search methods including target name, target physiological function, adverse effect, ligand name, and biological pathways. A special page is provided for contribution of new or additional information. This database can be accessed at http://​xin.​cz3.​nus.​edu.​sg/​group/​drt/​dart.​asp.
Literatur
1.
Zurück zum Zitat Pumford NR, Halmes NC. Protein targets of xenobiotic reactive intermediates. Annu Rev Pharmacol Toxicol 1997; 37: 91–117PubMedCrossRef Pumford NR, Halmes NC. Protein targets of xenobiotic reactive intermediates. Annu Rev Pharmacol Toxicol 1997; 37: 91–117PubMedCrossRef
2.
Zurück zum Zitat Wallace KB, Starkov AA. Mitochondrial targets of drug toxicity. Annu Rev Pharmacol Toxicol 2000; 40: 353–88PubMedCrossRef Wallace KB, Starkov AA. Mitochondrial targets of drug toxicity. Annu Rev Pharmacol Toxicol 2000; 40: 353–88PubMedCrossRef
3.
Zurück zum Zitat Park BK, Kitteringham NR, Powell H, et al. Advances in molecular toxicology: towards understanding idiosyncratic drug toxicity. Toxicology 2000; 153: 39–60PubMedCrossRef Park BK, Kitteringham NR, Powell H, et al. Advances in molecular toxicology: towards understanding idiosyncratic drug toxicity. Toxicology 2000; 153: 39–60PubMedCrossRef
4.
Zurück zum Zitat Rang HP, Dale MM, Ritter JM. Pharmacology. 4th ed. New York: Churchill Livingstone, 1999 Rang HP, Dale MM, Ritter JM. Pharmacology. 4th ed. New York: Churchill Livingstone, 1999
5.
Zurück zum Zitat Klaassen CD. Casarett and Doull’s toxicology: the basic science of poisons. 6th ed. New York: Mcgraw-Hill, 2001 Klaassen CD. Casarett and Doull’s toxicology: the basic science of poisons. 6th ed. New York: Mcgraw-Hill, 2001
6.
Zurück zum Zitat Baynes J, Dominiczak MH. Medical biochemistry. St Louis: Mosby, 1999 Baynes J, Dominiczak MH. Medical biochemistry. St Louis: Mosby, 1999
7.
Zurück zum Zitat Kong AN, Mandlekar S, Yu R, et al. Pharmacodynamics and toxicodynamics of drug action: signalling in cell survival and cell death. Pharm Res 1999; 16: 790–8PubMedCrossRef Kong AN, Mandlekar S, Yu R, et al. Pharmacodynamics and toxicodynamics of drug action: signalling in cell survival and cell death. Pharm Res 1999; 16: 790–8PubMedCrossRef
8.
Zurück zum Zitat Monks TJ, Lau SS. The pharmacology and toxicology of polyphenolic-glutathione conjugates. Annu Rev Pharmacol Toxicol 1998; 38: 229–55PubMedCrossRef Monks TJ, Lau SS. The pharmacology and toxicology of polyphenolic-glutathione conjugates. Annu Rev Pharmacol Toxicol 1998; 38: 229–55PubMedCrossRef
9.
Zurück zum Zitat Gerhold D, Rushmore T, Caskey CT. DNA chips: promising toys have become powerful tools. Trends Biochem Sci 1999; 24: 168–73PubMedCrossRef Gerhold D, Rushmore T, Caskey CT. DNA chips: promising toys have become powerful tools. Trends Biochem Sci 1999; 24: 168–73PubMedCrossRef
10.
Zurück zum Zitat Nuwaysir EF, Bittner M, Trent J, et al. Microarrays and toxicology: the advent of toxicogenomics. Mol Carcinog 1999; 24: 153–9PubMedCrossRef Nuwaysir EF, Bittner M, Trent J, et al. Microarrays and toxicology: the advent of toxicogenomics. Mol Carcinog 1999; 24: 153–9PubMedCrossRef
11.
Zurück zum Zitat Barratt MD. Integrating computer prediction systems with in vitro methods towards a better understanding of toxicology. Toxicol Lett 1998; 102-103: 617–21PubMedCrossRef Barratt MD. Integrating computer prediction systems with in vitro methods towards a better understanding of toxicology. Toxicol Lett 1998; 102-103: 617–21PubMedCrossRef
12.
Zurück zum Zitat Chen YZ, Ung CY. Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach. J Mol Graph Model 2001; 5278: 1–20 Chen YZ, Ung CY. Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach. J Mol Graph Model 2001; 5278: 1–20
13.
Zurück zum Zitat Peltonen L, Mckusick VA. Genomics and medicine: dissecting human disease in the postgenomics era. Science 2001; 291: 1224–32PubMedCrossRef Peltonen L, Mckusick VA. Genomics and medicine: dissecting human disease in the postgenomics era. Science 2001; 291: 1224–32PubMedCrossRef
14.
15.
Zurück zum Zitat Koonin EV, Tatusov RL, Galperin MY. Beyond complete genomes: from sequence to structure and function. Curr Opin Struct Biol 1998 Jun; 8: 355–63PubMedCrossRef Koonin EV, Tatusov RL, Galperin MY. Beyond complete genomes: from sequence to structure and function. Curr Opin Struct Biol 1998 Jun; 8: 355–63PubMedCrossRef
16.
Zurück zum Zitat Smith LL. Key challenges for toxicologists in the 21st century. Trends Pharmacol Sci 2001; 22(6): 281–5PubMedCrossRef Smith LL. Key challenges for toxicologists in the 21st century. Trends Pharmacol Sci 2001; 22(6): 281–5PubMedCrossRef
17.
Zurück zum Zitat Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001; 22(6): 298–305PubMedCrossRef Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001; 22(6): 298–305PubMedCrossRef
18.
Zurück zum Zitat Vesell ES. Advances in pharmacogenetics and pharmacogenomics. J Clin Pharmacol 2000; 40: 930–8PubMedCrossRef Vesell ES. Advances in pharmacogenetics and pharmacogenomics. J Clin Pharmacol 2000; 40: 930–8PubMedCrossRef
19.
Zurück zum Zitat McEntyre J, Lipman D. Pubmed: bridging the information gap. CMAJ 2001; 164(9): 1317–9PubMed McEntyre J, Lipman D. Pubmed: bridging the information gap. CMAJ 2001; 164(9): 1317–9PubMed
20.
Zurück zum Zitat Rauws AG, De Waal EJ, Van Der Laan JW. Sense and nonsense in toxicity assessment of medicinal products. Adv Drug Res 1997; 30: 15–72CrossRef Rauws AG, De Waal EJ, Van Der Laan JW. Sense and nonsense in toxicity assessment of medicinal products. Adv Drug Res 1997; 30: 15–72CrossRef
21.
Zurück zum Zitat Mitchell JA, Gillam EM, Stanley LA, et al. Immunotoxic side-effects of drug therapy. Drug Saf 1990; 5: 168–78PubMedCrossRef Mitchell JA, Gillam EM, Stanley LA, et al. Immunotoxic side-effects of drug therapy. Drug Saf 1990; 5: 168–78PubMedCrossRef
22.
23.
Zurück zum Zitat Wang TS, Shu YF, Liu YC, et al. Glutathione peroxidase and catalase modulate the genotoxicity of arsenite. Toxicology 1997; 121: 229–37PubMedCrossRef Wang TS, Shu YF, Liu YC, et al. Glutathione peroxidase and catalase modulate the genotoxicity of arsenite. Toxicology 1997; 121: 229–37PubMedCrossRef
24.
Zurück zum Zitat Surtees R, Blau N. The neurochemistry of phenylketonuria. Eur J Pediatr 2000; 159Suppl. 2: 109–13CrossRef Surtees R, Blau N. The neurochemistry of phenylketonuria. Eur J Pediatr 2000; 159Suppl. 2: 109–13CrossRef
25.
Zurück zum Zitat Robinson DR. Prostaglandins and the mechanism of action of anti-inflammatory drugs. Am J Med 1983 Oct 31; 75(4B): 26–31PubMedCrossRef Robinson DR. Prostaglandins and the mechanism of action of anti-inflammatory drugs. Am J Med 1983 Oct 31; 75(4B): 26–31PubMedCrossRef
26.
Zurück zum Zitat Howell RE, Muehsam WT, Kinnier WJ. Mechanism for the emetic side effect of xanthine bronchodilators. Life Sci 1990; 46(8): 563–8PubMedCrossRef Howell RE, Muehsam WT, Kinnier WJ. Mechanism for the emetic side effect of xanthine bronchodilators. Life Sci 1990; 46(8): 563–8PubMedCrossRef
27.
Zurück zum Zitat Alderman CP. Perhexiline-paroxetine drug interaction. Aust J Hosp Pharm 1998; 28: 254–5 Alderman CP. Perhexiline-paroxetine drug interaction. Aust J Hosp Pharm 1998; 28: 254–5
28.
Zurück zum Zitat Bairoch A Apweiler R. The SWISS-PROT protein sequence database and its supplement tremble in 2000. Nucleic Acids Res 2000; 28: 45–8PubMedCrossRef Bairoch A Apweiler R. The SWISS-PROT protein sequence database and its supplement tremble in 2000. Nucleic Acids Res 2000; 28: 45–8PubMedCrossRef
29.
Zurück zum Zitat Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000; 28: 235–42PubMedCrossRef Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000; 28: 235–42PubMedCrossRef
30.
31.
Zurück zum Zitat Scharpe S, De Meester I. Peptide truncation by dipeptidyl peptidase IV: a new pathway for drug discovery? Verh K Acad Geneeskd Belg 2001; 63(1): 5–32PubMed Scharpe S, De Meester I. Peptide truncation by dipeptidyl peptidase IV: a new pathway for drug discovery? Verh K Acad Geneeskd Belg 2001; 63(1): 5–32PubMed
Metadaten
Titel
Drug Adverse Reaction Target Database (DART)
Proteins Related to Adverse Drug Reactions
verfasst von
Zhi Liang Ji
Lian Yi Han
Chun Wei Yap
Li Zhi Sun
Xin Chen
Dr Yu Zong Chen
Publikationsdatum
01.08.2003
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 10/2003
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200326100-00002

Weitere Artikel der Ausgabe 10/2003

Drug Safety 10/2003 Zur Ausgabe

Practical Drug Safety

Drug-Induced Myelosuppression